How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Here we describe a new array system (miRCURY TM LNA Array) for global microRNA (miRNA) profiling of biological samples. The miRCURY LNA Array system uses locked nucleic acid (LNA TM), a high-affinity ...

National security, unlocked. Each Thursday, host Mary Louise Kelly and a team of NPR correspondents discuss the biggest national security news of the week. With decades of reporting from battlefields ...

Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. Any time you tap, swipe or dip a credit or debit card at checkout or enter your card number online, you ...

Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. Vikki Velasquez is a researcher and writer who has managed, coordinated, ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...